Cost-Effectiveness Analysis of Intravitreal Aflibercept Compared with Ranibizumab-Prn in Patients with wet Age-Related Macular Degeneration (Wamd)
Nov 1, 2015, 00:00
10.1016/j.jval.2015.09.067
https://www.valueinhealthjournal.com/article/S1098-3015(15)02143-9/fulltext
Title :
Cost-Effectiveness Analysis of Intravitreal Aflibercept Compared with Ranibizumab-Prn in Patients with wet Age-Related Macular Degeneration (Wamd)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)02143-9&doi=10.1016/j.jval.2015.09.067
First page :
A880
Section Title :
Research Podium Presentations - Session 1
Open access? :
No
Section Order :
2816